Advanced searches left 3/3

ANTAGONIST - Europe PMC

Summarized by Plex Scholar
Last Updated: 10 August 2022

* If you want to update the article please login/register

A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation.

Patients with aortic valvular disease are increasingly receiving transcatheter aortic valve replacement therapy. Patients undergoing TAVR have Atrial fibrillation, a common comorbidity. Despite this, there is a paucity of evidence and well-established guidelines on anticoagulation use in patients with AF. Vitamin K antagonists were included in seven studies, with 9764 patients on non-vitamin K antagonist oral anticoagulants and 15,435 patients on vitamin K antagonists included in the study. There were no detectable differences between patients on NOAC and VKA for all-cause mortality at 2 years, stroke within 30 days, stroke within 1 year, ischaemic stroke at 1 year, and life-threatening bleeding at 30 days. Conclusions Although the results of this review indicate NOAC as a potential alternate treatment modality to VKA in post-TAVR patients with AF, more research is required to determine the complete safety and effectiveness profile of NOAC.

Source link: https://europepmc.org/article/MED/35941300


A peripheral opioid antagonist for treating urinary retention induced by opioids: A case report.

Urinary retention is a poorly studied adverse effect linked to opioid use, which is mainly discussed. There is a lack of evidence regarding the management of such instability in patients with advanced cancer receiving opioids. Despite success, a young man without comorbidities was given 30 mg of oxycodone for abdominal pain as a result of pancreatic cancer. Methadone therapy was helpful on pain relief, but bladder dysfunction remained. Optional courses of action Only anedoctal evidence has been found for opioid-induced urinary retention. Hence, naldemedine 200 mg was used for relieving urinary retention. Outcome The day after starting naldemedine, urinary retention completely reversed, and pain was well-controlled, with no sign of discomfort. Lessons was based on the use of opioid-induced urinary retention due to the presence of peripheral receptors in the bladder and sphincter. View & View In this case report, the effect of the peripheral opioid antagonist was prompt and long-lived.

Source link: https://europepmc.org/article/MED/35941754


Recombinant LH supplementation improves cumulative live birth rates in the GnRH antagonist protocol: a multicenter retrospective study using a propensity score-matching analysis.

However, the benefits of recombinant follicle stimulating hormone supplementation in the gonadotrophin releasing hormone therapy regimen are split. Methods This multicenter retrospective cohort study examined 899 GnRH antagonist cycles in 3 reproductive centers and matched them to 2652 r-FSH stimulating cycles, using propensity score matching for potential confounders in a 1:3 ratio. Both fresh embryo transfer cycles and frozen embryo transfer cycles resulted in a higher 2-pronuclear embryo rate, usable embryo rate, and live birth rate in both new embryo transfer cycles and frozen embryo transfer cycles. Conclusions R-LH supplementation in the GnRH antagonist program was significantly associated with a higher CLBR and live birth rate in fresh and FET cycles, as well as improved embryo quality without raising the OHSS rate and cycle cancellation rate.

Source link: https://europepmc.org/article/MED/35941630


IL-36 receptor agonist and antagonist imbalance drives neutrophilic inflammation in COPD.

In bronchoalveolar and nasal fluid, COPD patients have elevated IL-36, upturned IL-3 and reduced IL-36 receptor antagonist, as well as in control subjects. Proteases isolated from COPD neutrophils cleave and activate IL-36 (u03b3), perpetuating IL-36 inflammation, perpetuating IL-36 disease. The use of a therapeutic antibody that blocks binding to the IL-36R attenuated IL-36R-driven inflammation and cell crosstalk. We've developed a way for the amplification and propagation of neutrophilic inflammation in COPD, and we've shown that blocking this cytokine family by an IL-36R neutralizing antibody might be a promising therapeutic treatment.

Source link: https://europepmc.org/article/MED/35763349


Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin.

Methods A retrospective cohort study of 171-IVF patients at risk of developing OHSS following a GnRH agonist cycle with HCG trigger was conducted from 2011 to 2019. Orally and ganirelix, 250 mg SC for 7-10 days, orally for 7 days, women were converted to a freeze-all cycle and were sent either cabergoline 0. 5 mg orally alone for 7 days from the collection orally alone for 7 days. Group 1 had more cases of moderate to severe OHSS than group 2-, with more cases of moderate and severe OHSS. More abdominal pain and bloating than group 2 were experienced in group 1 than group 2, and free fluid supply was more prevalent in group 1 than group 2. The addition of GnRH antagonists in the luteal phase can reduce the risk of developing moderate and severe OHSS in patients at high risk of OHSS after hCG stimulation in a GnRH agonist cycle.

Source link: https://europepmc.org/article/MED/35932297


Agonist-antagonist muscle strain in the residual limb preserves motor control and perception after amputation.

The connection between preserved agonist-antagonist muscle strain inside the residual leg and preserved motor control and perception capacity is explored in this study. The deposition of muscle synergies in biologically intact limbs is achieved by varied motor control in biologically intact limbs, according to study. Here, we investigate the innateness of phantom joint motor control postamputation based on isolated muscle synergies and activation profiles. According to established statistics, retaining even 20-26% of agonist-antagonist muscle strain within the residuum as opposed to a biologically healthy limb is highly recommended in preserving natural motor control postamputation, but retaining leg perception capacity requires more agonist-antagonist muscle strain preservation. Conclusions The results show that agonist-antagonist muscle strain is a common, easily identifiable residual limb structural characteristic that can help explain variability in amputation result, and agonist-antagonist muscle strain preservation methods are one way to promote more effective and biomimetic sensorimotor control postamputation.

Source link: https://europepmc.org/article/MED/35942078


Comparison of the cumulative live birth rates after 1 in vitro fertilization cycle in women using gonadotropin-releasing hormone antagonist protocol vs. progestin-primed ovarian stimulation: a propensity score-matched study.

In unselected patients compared to progestin-primed ovarian stimulation, it is likely that gonadotropin-releasing hormone antagonist therapy can raise cumulative live birth rates and shorten the time to live birth. Patient A total of 6,520 women with infertility aged 20 to 50 years were included. Result After propensity score matching, each group became 1,424 couples, and baseline demographic data of the couples after matching were comparable between the two groups. In the GnRH antagonist group's cycle cancellation rate was significantly lower than in the PPOS group. However, CLBRs after a complete IVF cycle were significantly higher in the GnRH antagonist group than in the PPOS group. In the GnRH antagonist group than in the PPOS group, the average TTLB was significantly shorter than that in the PPOS group. The cumulative incidence of continuing pregnancy leading to live birth in the GnRH antagonist group was significantly higher than in the PPOS group, according to the Kaplan-Meier report. According to a Cox proportional hazard analysis, women who underwent the antagonist protocol were 2. 32 times more likely to have a live birth than those who used PPOS. According to the 3 antral follicle count strata, 2 age strata, and first cycle or repeated cycle, women who used the antagonist protocol were more likely to have a live birth than those who used PPOS across the 3 antral follicle count strata, 2 age strata, and first cycle or repeated cycle. In contrast to PPOS, the GnRH antagonist treatment was associated with a higher CLBR and a shorter TTLB.

Source link: https://europepmc.org/article/MED/35940929


Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD : A retrospective cohort study in a real-world setting

Background: Pneumonia is a chronic respiratory disease that is often associated with chronic obstructive pulmonary disease. However, few studies have directly compared the incidence of pneumonia in patients on common COPD drugs such as long-acting muscarinic antagonists, with those on inhaled corticosteroids and long-acting u03b2 2 agonists. In addition, the risk factors for pneumonia in COPD are also uncertain. We compared pneumonia in COPD patients on LAMA and those on ICS/LABA and those on ICS/LABA, examining the risk factors associated with pneumonia. Methods This national cohort analysis used Korean National Health Insurance claim data from January 2002 to April 2016. Patients receiving COPD medications, either LAMA or ICS/LABA, with the COPD diagnostic code, were selected. Conclusions The prevalence of pneumonia in COPD patients on ICS/LABA was higher than those on LAMA. In COPD patients with elevated pneumonia risk, it is highly recommended that ICS use be avoided.

Source link: https://europepmc.org/article/PPR/PPR528481


Neutrophil extracellular traps are involved in enhanced contact hypersensitivity response in IL-36 receptor antagonist-deficient mice.

We hypothesized that NETs could play a significant role in the CHS' response. In addition, the CHS response was improved thanks to NET formation blockade, which also decreased inflammation cell infiltration and NET formation. These results show that IL-36Ra deficiencies, NET growth, and cytokine and chemokine manufacturing all escalates the CHS reaction, which leads to increased CHS responses, prompting CHS responses, which are exacerbated by increased inflammatory cell recruitment, NET formation, and chemokine production. Also, the NET formation blockade alleviates the CHS response. Hence, NET development may play a crucial role in the CHS' response.

Source link: https://europepmc.org/article/MED/35927298


Antagonist tendon vibration dampens estimates of persistent inward currents in motor units of the human lower limb

ABSTRACT We can now determine motoneuron discharge patterns in humans as a result of the one-to-one relationship between motoneuroneuron and muscle fiber action potentials, which allows us to draw inferences about motor commands. PICs were estimated using the paired MU analysis method, which quantifies discharge rate hysteresis by comparing the discharge rate of a lower-threshold MU at the onset and offset of a higher-threshold MU. In half of the trials, we applied vibration to the antagonist tendon and found that u0394F in agonist MUs decreased in the presence of vibration. In both the plantarflexors and dorsiflexors, we show that continued resistance to the antagonist tendon reduces estimates of persistent inward currents of the contracting muscle in both the plantarflexors and dorsiflexors. Reciprocal inhibition may help tailor motor unit activation to various mobility preferences and specific tasks, and loss of inhibition may exacerbate neurological impairment symptoms.

Source link: https://europepmc.org/article/PPR/PPR528018

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions